Multi-center Prospective Study Determining the Sustainability of Pain Relief and Psychosocial and Functional Responses When Utilizing a Multiple Waveform Enabled Neurostimulator

Not Applicable

Completed

Conditions: Intractable Pain
Chronic Pain

Interventions: Device: Prodigy, Prodigy MRI or Proclaim Elite IPG

Registration Number: NCT03082261

Lead Sponsor: Abbott Medical Devices

Brief Summary: The TRIUMPH study is a post-market, international, multicenter, interventional, prospective, single-arm study intended to evaluate the sustainability of pain control and psychosocial and functional responses utilizing a multiple-waveform enabled neurostimulator in subjects with chronic, intractable pain of the trunk and/or limbs.

Detailed Description: TRIUMPH study will utilize the multiprogram trial stimulator or invisible trial system with BurstDR for the trial evaluation period and the Prodigy or Proclaim Elite family of neurostimulators with tonic or BurstDR waveform at permanent implant and follow-up for pain control and improvement of psychosocial function. The follow-up visits will be scheduled at 3, 6, 12, 18, and 24 months post permanent implant

Recruitment & Eligibility

Status: COMPLETED

Sex: All

Target Recruitment: 269

Inclusion Criteria

Subject has chronic, intractable pain of the trunk and/or limbs, including unilateral or bilateral pain associated with the following: failed back surgery syndrome and intractable low back and leg pain.
Subject has a score of 6 or higher on the numeric rating scale (NRS) for average pain specific to the area(s) of chronic pain being treated over the past 24 hours at the baseline visit.
Subject is considered by the Investigator as a candidate for implantation of a spinal cord stimulator system according to the system Instructions For Use.
Subject is 18 years of age or older at the time of enrollment.
Subject is willing to cooperate with the study requirements including compliance with the regimen and completion of all study visits.
Subject has signed and received a copy of the Ethics Committee/Institutional Review Board (EC/IRB) approved informed consent.

Exclusion Criteria

Subject currently has a spinal cord stimulation system implanted.
Subject has previously failed spinal cord stimulation (SCS) therapy (either trial system evaluation or permanent implant).
Subject has a primary diagnosis of Peripheral Vascular Disease (PVD), Angina Pectoris, or Chronic Migraine.
Subject has or plans to have a Peripheral Nerve Stimulation system (PNS), Peripheral Nerve field Stimulation system (PNfS), Dorsal Root Ganglion system (DRG), or implantable infusion pump.
Subject is currently participating in another clinical investigation with an active treatment arm.
Subject unable to read and/or write.

Study & Design

Study Type: INTERVENTIONAL

Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
All enrolled subjects	Prodigy, Prodigy MRI or Proclaim Elite IPG	All subjects enrolled into the study with intent to treat with either a Prodigy, Prodigy MRI, or Proclaim Elite Implantable Pulse Generator (IPG).

Primary Outcome Measures

Name	Time	Method
Mean Change in Pain From Baseline to 6 Months Post-permanent Implant, Assessed by the Numeric Rating Scale (NRS)	Baseline to 6 Months	The pain NRS consists of 1 question that will be asked by interviewing the subjects. Patients will be asked to rate, from 0 (no pain) to 10 (worst imaginable pain), their average pain over the past 24 hours specific to the area(s) of chronic pain being treated. A higher score indicates greater pain intensity.

Secondary Outcome Measures

Name	Time	Method
Mean Change in Depression From Baseline to 6 Months Post-permanent Implant, Assessed by the Patient Health Questionnaire-9 (PHQ9)	Baseline to 6 Months	The PHQ9 is a multipurpose, validated instrument for screening, diagnosing, monitoring and measuring the severity of depression. The questionnaire consists of 9 questions that rate the frequency of the symptoms of depression. A follow up non-scored question screens and assigns weight to the degree to which depressive problems have affected the patient's level of function. The responses range between 4 choices (0=not at all to 3=nearly every day). Higher scores indicate a higher likelihood of major depression. PHQ-9 scores range from 0 (min) to 27 (max).
Mean Change in Pain Catastrophizing From Baseline to 6 Months Post-permanent Implant, Assessed by the Pain Catastrophizing Scale (PCS)	Baseline to 6 Months	The PCS is a validated scale that measures the magnitude of catastrophizing (negative thoughts and feelings while a patient is experiencing pain). Subjects answer questions about how they feel and what they think about when they are in pain (i.e., not at the current moment). The scale includes 13 statements concerning pain experiences that are rated on a scale between 0 'not at all' and 4 'always'. The scale is self-administered and takes 5 minutes to complete. A higher score indicated a higher level of catastrophizing. PCS total scores range from 0 (min) to 52 (max). Three sub-scales consists of rumination, magnification, and helplessness. Rumination scores range from 0 (min) to 16 (max), Magnification scores range from 0 (min) to 12 (max), and helplessness scores range from 0 (min) to 24 (max). The total PCS score is the sum of the three subscales.
Mean Change in Sleep From Baseline to 6 Months Post-permanent Implant, Assessed by the Medical Outcome Study (MOS) Sleep Scale	Baseline to 6 Months	The MOS sleep scale is intended to assess the extent of sleep problems and measures 6 dimensions of sleep, including initiation, maintenance, quantity, adequacy, drowsiness and respiratory impairments. It includes 12 questions with the first question assessing how long it takes the subject to fall asleep. The second question asks how many hours each night the subject slept. The remaining 10 questions have a range of 6 responses from 1="all of the time" to 6="none of the time". The scale is self-administered and validated. MOS Sleep scale scores range from 0 (min) to 100 (max). Higher scores represent worse outcomes.
Mean Change in Physical Function From Baseline to 6 Months Post-permanent Implant, Assessed by the Patient-Reported Outcome Measure Information System (PROMIS) Physical Function Scale	Baseline to 6 Months	The PROMIS Physical Function short form is an 8-item instrument designed to measure physical capability rather than actual performance of physical activities. The scale measures universal physical function rather than disease-specific impairment and assesses current function rather than function over a specified time period. Each question has five potential response options ranging in value from one to five to give a total score ranging from 8 to 40. Scores are converted into t-scores where the average for the general US population is 50 and the SD is 10. Higher scores indicate better physical function.
Mean Change in Fear Avoidance From Baseline to 6 Months Post-permanent Implant, Assessed by the Tampa Scale for Kinesiophobia (TSK)	Baseline to 6 Months	The TSK is a 11-item self-report checklist using a 4-point Likert scale that was developed from the original 17-item checklist (Miller, Kopri \& Todd, 1991) as a measure of fear or movement or (re)injury. The scale is based on the model of fear avoidance, fear of work related activities, fear of movement and fear of re-injury. The TSK has also been linked to elements of catastrophic thinking. The scale can be useful in measuring unhelpful thoughts and beliefs about pain in people with chronic pain. Total TSK-11 scores range from 11-44 points. Higher scores represent worse outcomes.
Mean Change in Quality of Life From Baseline to 6 Months Post-permanent Implant, Assessed by the EuroQuol-5 Dimensions (EQ5D) Questionnaire	Baseline to 6 Months	EQ5D is a standardized instrument for use as a measure of health outcome applicable to a wide range of health conditions and treatments. It provides a simple descriptive profile and a single index value for health status. The EQ5D-3L descriptive system comprises the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 3 levels: no problems, some problems, extreme problems. A visual analog scale (VAS) for health is also included in the measure as a patient-reported estimate of overall health status. EQ5D Index scores range from - 0.594 (min) to 1 (max). An EQ-5D summary index is derived by applying a formula that attaches values (weights) to each of the levels in each dimension. Higher values represent better outcomes.
Mean Change in Anxiety From Baseline to 6 Months Post-permanent Implant, Assessed by the State-Trait Anxiety Inventory (STAI)	Baseline to 6 Months	The State-Trait Anxiety inventory is a self-administered screening for anxiety. The STAI has 40 items, 20 items allocated to each of the S-Anxiety and T-Anxiety subscales. All items are rated on a 4-point scale from 1 to 4. It clearly differentiates between the temporary condition of "state anxiety" and the more general and long-standing quality of "trait anxiety" by providing a score for each. Higher scores suggest greater levels of anxiety. The range of possible scores for the STAI varies from a minimum score of 20 to a maximum score of 80 on both the trait and state subscales. The total score is the sum of the two subscales. STAI total scores range from 40 to 160.

Trial Locations

Locations (22): The CORE Institute
🇺🇸
Phoenix, Arizona, United States
Tory McJunkin MD
🇺🇸
Scottsdale, Arizona, United States
Hospital Universitario Puerta de Hierro
🇪🇸
Majadahonda, Spain
Ensemble Hospitalier de la Cote, Hopital de Morges
🇨🇭
Morges, Switzerland
St. Luke's Hospital & Health Network
🇺🇸
Bethlehem, Pennsylvania, United States
Performance Spine and Sports Physicians, P.C.
🇺🇸
Pottstown, Pennsylvania, United States
Azalea Orthopedics
🇺🇸
Tyler, Texas, United States
Neurochirurgische Praxis Neuss
🇩🇪
Neuss, North Rhine-Westphalia, Germany
Hospital Clinico Universitario Lozano Blesa
🇪🇸
Zaragoza, Aragon, Spain
Hospital Virgin de Rocio
🇪🇸
Sevilla, Andalusia, Spain
Hospital Universitari i Politecnic La Fe
🇪🇸
Valencia, Spain
Carolinas Center for Advanced Management of Pain
🇺🇸
Greenville, South Carolina, United States
CHA L'Enfant Jesus
🇨🇦
Quebec, Canada
Kuopio University Hospital
🇫🇮
Kuopio, Eastern Finland, Finland
Azienda Ospedaliero Univsitaria Pisana
🇮🇹
Pisa, Tuscany, Italy
Fondazione I.R.C.C.S. Instituto Neurologico Carlo Besta
🇮🇹
Milano, Lombardy, Italy
Clinical Trials of South Carolina
🇺🇸
Charleston, South Carolina, United States
Pacific Sports & Spine
🇺🇸
Eugene, Oregon, United States
Pain Institute of Southern Arizona
🇺🇸
Tucson, Arizona, United States
Advanced Pain Management
🇺🇸
Greenfield, Wisconsin, United States
Royal University Hospital
🇨🇦
Saskatoon, Saskatchewan, Canada
Chicago Anesthesia Associates, S.C.
🇺🇸
Chicago, Illinois, United States